JP2013545730A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545730A5 JP2013545730A5 JP2013535311A JP2013535311A JP2013545730A5 JP 2013545730 A5 JP2013545730 A5 JP 2013545730A5 JP 2013535311 A JP2013535311 A JP 2013535311A JP 2013535311 A JP2013535311 A JP 2013535311A JP 2013545730 A5 JP2013545730 A5 JP 2013545730A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- neuropathic pain
- pain
- syndrome
- lesions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (11)
- 神経因性疼痛及び/又は神経因性疼痛症候群の治療において使用するための化合物であって、
前記化合物は、化学式:
又は、化学式:
で示されるマロノニトリルアミド化合物、又は、その薬学的に許容される塩、溶媒和物、互変異性体若しくは立体異性体である化合物。 - 請求項1に記載の化合物において、
前記化合物の互変異性体は、ケト型又はエノール型の2−シアノ−3−オキソ−N−[4−(トリフルオロメチル)フェニル]−6−ヘプチンアミドである化合物。 - 請求項1又は2に記載の化合物において、
前記化合物の立体異性体は、R鏡像異性体又はS鏡像異性体である化合物。 - 請求項1〜3のいずれか1項に記載の化合物において、
前記化合物は、末梢の及び/又は主に末梢の神経因性疼痛、又は、中枢の及び/又は主に中枢の神経因性疼痛の治療において使用される化合物。 - 請求項4に記載の化合物において、
前記主に末梢の神経因性疼痛は、以下の神経因性疼痛の種類から選ばれる種類であるか、及び/又は以下の病因群から選ばれる病因を有し、
−全身性疾患、
−薬物誘発性病変、
−外傷性症候群及び絞扼性神経障害、
−神経根及び後神経節における病変、
−HIV感染後の神経障害、
−ヘルペス感染後の神経痛、
−神経根引き抜き損傷、
−脳神経病変、
−頭蓋神経痛、
−神経因性癌疼痛、
−幻肢痛、
−末梢神経、神経叢及び神経根の圧迫、
−腫瘍随伴性末梢神経障害及び神経節障害、
−癌治療による合併症、
−複合性局所疼痛症候群、
−I型病変、
−II型病変、
前記主に中枢の神経因性疼痛は、
−主に視床の脳病変、
−梗塞、
−視床や脳幹を圧迫する脳の腫瘍又は膿瘍、
−多発性硬化症、
−頭痛症候群、
−脳手術、
−脊髄障害、
−脊髄損傷、
−脊髄手術、
−虚血性病変、
−前脊髄動脈症候群、
−ワレンベルグ症候群、
−脊髄空洞症、
などの病因群から選ばれる病因を有するタイプのものである化合物。 - 請求項1〜3のいずれか1項に記載の化合物において、
前記神経因性疼痛症候群は、帯状疱疹後神経痛、神経根引き抜き損傷、疼痛を伴う外傷性単神経障害、疼痛を伴う多発性神経障害、中枢性疼痛症候群、術後痛症候群、複合性局所疼痛症候群、及び/又は、片頭痛若しくは片頭痛の痛みである化合物。 - 請求項1〜3のいずれか1項に記載の化合物において、
前記神経因性疼痛は、脊髄損傷及び/又は脊髄挫傷に起因する中枢性疼痛症候群である化合物。 - 請求項1〜7のいずれか1項に記載の化合物において、
前記神経因性疼痛は、慢性神経因性疼痛である化合物。 - 請求項1〜8のいずれか1項に記載の化合物において、
前記化合物は、神経系の損傷後に始まって、1mg/body〜10g/bodyの1日投与量で投与される化合物。 - 神経因性疼痛及び/又は神経因性疼痛症候群の治療において使用するための医薬組成物であって、
前記医薬組成物は、請求項1〜3のいずれか1項に記載の化合物を、遊離形態で又は薬学的に許容される塩若しくは生理機能性誘導体の形態で、薬学的に許容される希釈剤又は担体とともに含み、
前記神経因性疼痛は、請求項4〜8のいずれか1項に記載の神経因性疼痛及び/又は神経因性疼痛症候群である医薬組成物。 - 請求項10に記載の医薬組成物において、
前記化合物は、化学式:
を有する化合物、又は、その薬学的に許容される塩、溶媒和物、互変異性体、立体異性体である医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40819510P | 2010-10-29 | 2010-10-29 | |
US61/408,195 | 2010-10-29 | ||
EP10014122 | 2010-10-29 | ||
EP10014122.5 | 2010-10-29 | ||
PCT/EP2011/005452 WO2012055567A2 (en) | 2010-10-29 | 2011-10-28 | Use of malononitrilamides in neuropathic pain |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013545730A JP2013545730A (ja) | 2013-12-26 |
JP2013545730A5 true JP2013545730A5 (ja) | 2014-10-16 |
JP6257326B2 JP6257326B2 (ja) | 2018-01-10 |
Family
ID=44992853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013535311A Active JP6257326B2 (ja) | 2010-10-29 | 2011-10-28 | 神経因性疼痛におけるマロノニトリルアミドの使用 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20130217737A1 (ja) |
EP (1) | EP2632451B1 (ja) |
JP (1) | JP6257326B2 (ja) |
CN (1) | CN103179962B (ja) |
CA (1) | CA2814371C (ja) |
DK (1) | DK2632451T3 (ja) |
ES (1) | ES2655084T3 (ja) |
HR (1) | HRP20171848T1 (ja) |
HU (1) | HUE034890T2 (ja) |
LT (1) | LT2632451T (ja) |
NO (1) | NO2632451T3 (ja) |
PL (1) | PL2632451T3 (ja) |
PT (1) | PT2632451T (ja) |
RS (1) | RS56713B1 (ja) |
SI (1) | SI2632451T1 (ja) |
WO (1) | WO2012055567A2 (ja) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
ES2797624T3 (es) | 2012-05-23 | 2020-12-03 | Cellix Bio Private Ltd | Composición para el tratamiento de la enfermedad inflamatoria intestinal |
WO2013175344A2 (en) * | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
CA2873029A1 (en) | 2012-09-08 | 2014-03-13 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
CA2914461A1 (en) | 2013-06-04 | 2014-12-11 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
AU2014407862B2 (en) | 2014-09-29 | 2020-03-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
MA45202B1 (fr) * | 2016-09-24 | 2022-04-29 | Kbp Biosciences Co Ltd | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation |
PL3928772T3 (pl) | 2020-06-26 | 2024-10-07 | Algiax Pharmaceuticals Gmbh | Kompozycja nanocząstkowa |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
KR100188801B1 (ko) | 1990-05-18 | 1999-06-01 | 엥겔하르트 라피체 | 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물 |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
GB9200275D0 (en) | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
FR2727628B1 (fr) * | 1994-12-02 | 1997-01-10 | Roussel Uclaf | Application des derives de 3-cycloalkyl-propanamide a titre de medicaments analgesiques |
US6566395B1 (en) * | 1999-05-25 | 2003-05-20 | Biomedicines, Inc. | Methods of treating proliferative disorders |
GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
CN103153295A (zh) * | 2010-08-24 | 2013-06-12 | 艾格埃克斯制药有限公司 | 来氟米特和丙二腈酰胺类似物的新用途 |
-
2011
- 2011-10-28 ES ES11784418.3T patent/ES2655084T3/es active Active
- 2011-10-28 JP JP2013535311A patent/JP6257326B2/ja active Active
- 2011-10-28 PT PT117844183T patent/PT2632451T/pt unknown
- 2011-10-28 LT LTEP11784418.3T patent/LT2632451T/lt unknown
- 2011-10-28 SI SI201131372T patent/SI2632451T1/en unknown
- 2011-10-28 HU HUE11784418A patent/HUE034890T2/hu unknown
- 2011-10-28 PL PL11784418T patent/PL2632451T3/pl unknown
- 2011-10-28 DK DK11784418.3T patent/DK2632451T3/en active
- 2011-10-28 WO PCT/EP2011/005452 patent/WO2012055567A2/en active Application Filing
- 2011-10-28 CA CA2814371A patent/CA2814371C/en active Active
- 2011-10-28 NO NO11784418A patent/NO2632451T3/no unknown
- 2011-10-28 US US13/880,139 patent/US20130217737A1/en not_active Abandoned
- 2011-10-28 CN CN201180051334.6A patent/CN103179962B/zh active Active
- 2011-10-28 EP EP11784418.3A patent/EP2632451B1/en active Active
- 2011-10-28 RS RS20171305A patent/RS56713B1/sr unknown
-
2014
- 2014-07-10 US US14/328,035 patent/US9468615B2/en active Active
-
2017
- 2017-11-28 HR HRP20171848TT patent/HRP20171848T1/hr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013545730A5 (ja) | ||
HRP20171848T1 (hr) | Upotreba malononitrilamida za neuropatsku bol | |
JP2012530779A5 (ja) | ||
RU2012101947A (ru) | Способы лечения и профилактики усталости | |
JP2016534063A5 (ja) | ||
JP2009504763A5 (ja) | ||
JP2019515908A5 (ja) | ||
RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
RU2013113634A (ru) | Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств | |
FI3681857T3 (fi) | Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa | |
JP2015524423A5 (ja) | ||
JP2015522018A5 (ja) | ||
US20100087457A1 (en) | Dosages and methods for the treatment of cancer | |
RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
JP2011518168A5 (ja) | ||
EP2144886A1 (en) | Method of treating melanoma | |
JP2016537432A5 (ja) | ||
JP2014530204A5 (ja) | ||
RU2019102757A (ru) | Производные этинила | |
JP2017516829A5 (ja) | ||
RU2018130097A (ru) | Лечение экземы кистей | |
JP2010509389A (ja) | 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ[1,2−a]イミダゾールジオン | |
RU2013148627A (ru) | Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии | |
RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
JP2014509637A5 (ja) |